Skip to main content
NCBI home page
American Journal of Human Genetics logoLink to American Journal of Human Genetics
. 1992 Jan;50(1):92–106.

Patterns of association between genetic variability in apolipoprotein (apo) B, apo AI-CIII-AIV, and cholesterol ester transfer protein gene regions and quantitative variation in lipid and lipoprotein traits: influence of gender and exogenous hormones.

A Kessling 1, S Ouellette 1, O Bouffard 1, A Chamberland 1, C Bétard 1, E Selinger 1, M Xhignesse 1, S Lussier-Cacan 1, J Davignon 1
PMCID: PMC1682540  PMID: 1346081

Abstract

Patterns of RFLP association were studied, to identify gene regions influencing quantitative variation in lipid and lipoprotein traits (coronary artery disease [CAD] risk factors or metabolically related traits). Subjects (118 female and 229 male; age 20-59 years) were selected for health. Multiple RFLPs were used to sample variability in regions around genes for apolipoprotein (apo) B (restriction enzymes HincII, PvuII, EcoRI, and XbaI), apo AI-CIII-AIV (BamHI, XmnI, TaqI, PstI, SstI, and PvuII) and cholesterol ester transfer protein (TaqI). Separate analyses were done by gender. The sample was truncated at mean +/- 4 SD, to remove extreme outliers. There was no significant gender difference in RFLP genotype frequency distribution. After trait-level adjustment to maximize removal of concomitant variability, analysis of variance was used to estimate the percentage trait phenotypic variance explained by measured variability in the gene regions studied. Fewer gene regions were involved in men, with less influence on quantitative trait variation than in women, in whom hormone use affected association patterns. Gender differences imply that pooling genders or adjusting data for gender effects removes genetic information and should be avoided. The association patterns show that variability around the candidate genes modulates trait levels: the genes are contributors to the genetics of CAD risk variables in a healthy sample.

Full text

PDF
92

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baird P. A. Genetics and health care: a paradigm shift. Perspect Biol Med. 1990 Winter;33(2):203–213. doi: 10.1353/pbm.1990.0009. [DOI] [PubMed] [Google Scholar]
  2. Cohen T., Karathanasis S. K., Kazazian H. H., Jr, Antonarakis S. E. DNA polymorphic sites in the human ApoAI-CIII-AIV cluster: Taq I and Ava I. Nucleic Acids Res. 1986 Feb 25;14(4):1924–1924. doi: 10.1093/nar/14.4.1924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Crouse J. R., 3rd Progress in coronary artery disease risk-factor research: what remains to be done? Clin Chem. 1984 Jul;30(7):1125–1127. [PubMed] [Google Scholar]
  4. Darnfors C., Nilsson J., Protter A. A., Carlsson P., Talmud P. J., Humphries S. E., Whalström J., Wiklund O., Bjursell G. RFLPs for the human apolipoprotein B gene: HincII and PvuII. Nucleic Acids Res. 1986 Sep 11;14(17):7135–7135. doi: 10.1093/nar/14.17.7135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Davignon J., Gregg R. E., Sing C. F. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988 Jan-Feb;8(1):1–21. doi: 10.1161/01.atv.8.1.1. [DOI] [PubMed] [Google Scholar]
  6. Drayna D., Lawn R. Multiple RFLPs at the human cholesteryl ester transfer protein (CETP) locus. Nucleic Acids Res. 1987 Jun 11;15(11):4698–4698. doi: 10.1093/nar/15.11.4698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Frossard P. M., Gonzalez P. A., Protter A. A., Coleman R. T., Funke H., Assmann G. Pvu II RFLP in the 5' of the human apolipoprotein B gene. Nucleic Acids Res. 1986 May 27;14(10):4373–4373. doi: 10.1093/nar/14.10.4373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fruchart J. C., Kora I., Cachera C., Clavey V., Duthilleul P., Moschetto Y. Simultaneous measurement of plasma apolipoproteins A-I and B by electroimmunoassay. Clin Chem. 1982 Jan;28(1):59–62. [PubMed] [Google Scholar]
  9. Grundy S. M. Cholesterol and coronary heart disease. A new era. JAMA. 1986 Nov 28;256(20):2849–2858. [PubMed] [Google Scholar]
  10. Haviland M. B., Kessling A. M., Davignon J., Sing C. F. Estimation of Hardy-Weinberg and pairwise disequilibrium in the apolipoprotein AI-CIII-AIV gene cluster. Am J Hum Genet. 1991 Aug;49(2):350–365. [PMC free article] [PubMed] [Google Scholar]
  11. Hobbs H. H., Brown M. S., Russell D. W., Davignon J., Goldstein J. L. Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia. N Engl J Med. 1987 Sep 17;317(12):734–737. doi: 10.1056/NEJM198709173171204. [DOI] [PubMed] [Google Scholar]
  12. Huang L. S., Ripps M. E., Breslow J. L. Molecular basis of five apolipoprotein B gene polymorphisms in noncoding regions. J Lipid Res. 1990 Jan;31(1):71–77. [PubMed] [Google Scholar]
  13. Humphries S. E. DNA polymorphisms of the apolipoprotein genes--their use in the investigation of the genetic component of hyperlipidaemia and atherosclerosis. Atherosclerosis. 1988 Aug;72(2-3):89–108. doi: 10.1016/0021-9150(88)90069-x. [DOI] [PubMed] [Google Scholar]
  14. Jeenah M., Kessling A., Miller N., Humphries S. G to A substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI and high density lipoprotein cholesterol concentrations. Mol Biol Med. 1990 Jun;7(3):233–241. [PubMed] [Google Scholar]
  15. Karathanasis S. K., Zannis V. I., Breslow J. L. Isolation and characterization of cDNA clones corresponding to two different human apoC-III alleles. J Lipid Res. 1985 Apr;26(4):451–456. [PubMed] [Google Scholar]
  16. Kessling A. M., Horsthemke B., Humphries S. E. A study of DNA polymorphisms around the human apolipoprotein AI gene in hyperlipidaemic and normal individuals. Clin Genet. 1985 Oct;28(4):296–306. doi: 10.1111/j.1399-0004.1985.tb00403.x. [DOI] [PubMed] [Google Scholar]
  17. Kessling A. M., Nanjee M. N., Miller N. E., Humphries S. E. Variations in the apolipoprotein AI-CIII-AIV gene region and in lecithin:cholesterol acyltransferase concentration are determinants of plasma cholesterol concentrations. Atherosclerosis. 1988 Mar;70(1-2):13–19. doi: 10.1016/0021-9150(88)90095-0. [DOI] [PubMed] [Google Scholar]
  18. Kessling A. M., Rajput-Wiliams J., Bainton D., Scott J., Miller N. E., Baker I., Humphries S. E. DNA polymorphisms of the apolipoprotein AII and AI-CIII-AIV genes: a study in men selected for differences in high-density-lipoprotein cholesterol concentration. Am J Hum Genet. 1988 Mar;42(3):458–467. [PMC free article] [PubMed] [Google Scholar]
  19. Kessling A. M., Taylor R., Temple A., Hutson J., Hidalgo A., Humphries S. E. A PvuII polymorphism in the 5' flanking region of the apolipoprotein AIV gene: its use to study genetic variation determining serum lipid and apolipoprotein concentration. Hum Genet. 1988 Mar;78(3):237–239. doi: 10.1007/BF00291668. [DOI] [PubMed] [Google Scholar]
  20. Law A., Wallis S. C., Powell L. M., Pease R. J., Brunt H., Priestley L. M., Knott T. J., Scott J., Altman D. G., Miller G. J. Common DNA polymorphism within coding sequence of apolipoprotein B gene associated with altered lipid levels. Lancet. 1986 Jun 7;1(8493):1301–1303. doi: 10.1016/s0140-6736(86)91222-5. [DOI] [PubMed] [Google Scholar]
  21. Leitersdorf E., Tobin E. J., Davignon J., Hobbs H. H. Common low-density lipoprotein receptor mutations in the French Canadian population. J Clin Invest. 1990 Apr;85(4):1014–1023. doi: 10.1172/JCI114531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Levy R. I. Declining mortality in coronary heart disease. Arteriosclerosis. 1981 Sep-Oct;1(5):312–325. doi: 10.1161/01.atv.1.5.312. [DOI] [PubMed] [Google Scholar]
  23. Lewis B., Chait A., Wootton I. D., Oakley C. M., Krikler D. M., Sigurdsson G., February A., Maurer B., Birkhead J. Frequency of risk factors for ischaemic heart-disease in a healthy British population. With particular reference to serum-lipoprotein levels. Lancet. 1974 Feb 2;1(7849):141–146. doi: 10.1016/s0140-6736(74)92438-6. [DOI] [PubMed] [Google Scholar]
  24. Lusis A. J. Genetic factors affecting blood lipoproteins: the candidate gene approach. J Lipid Res. 1988 Apr;29(4):397–429. [PubMed] [Google Scholar]
  25. Mailly F., Xu C. F., Xhignesse M., Lussier-Cacan S., Talmud P. J., Davignon J., Humphries S. E., Nestruck A. C. Characterization of a new apolipoprotein E5 variant detected in two French-Canadian subjects. J Lipid Res. 1991 Apr;32(4):613–620. [PubMed] [Google Scholar]
  26. Morris S. W., Price W. H. DNA sequence polymorphisms in the apolipoprotein A-I/C-III gene cluster. Lancet. 1985 Nov 16;2(8464):1127–1128. doi: 10.1016/s0140-6736(85)90718-4. [DOI] [PubMed] [Google Scholar]
  27. Oettgen P., Antonarakis S. E., Karathanasis S. K. PvuII polymorphic site upstream to the human ApoCIII gene. Nucleic Acids Res. 1986 Jul 11;14(13):5571–5571. doi: 10.1093/nar/14.13.5571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Parra H. J., Mezdour H., Ghalim N., Bard J. M., Fruchart J. C. Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. Clin Chem. 1990 Aug;36(8 Pt 1):1431–1435. [PubMed] [Google Scholar]
  29. Protter A. A., Hardman D. A., Schilling J. W., Miller J., Appleby V., Chen G. C., Kirsher S. W., McEnroe G., Kane J. P. Isolation of a cDNA clone encoding the amino-terminal region of human apolipoprotein B. Proc Natl Acad Sci U S A. 1986 Mar;83(5):1467–1471. doi: 10.1073/pnas.83.5.1467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Pullinger C. R., North J. D., Teng B. B., Rifici V. A., Ronhild de Brito A. E., Scott J. The apolipoprotein B gene is constitutively expressed in HepG2 cells: regulation of secretion by oleic acid, albumin, and insulin, and measurement of the mRNA half-life. J Lipid Res. 1989 Jul;30(7):1065–1077. [PubMed] [Google Scholar]
  31. Rees A., Shoulders C. C., Stocks J., Galton D. J., Baralle F. E. DNA polymorphism adjacent to human apoprotein A-1 gene: relation to hypertriglyceridaemia. Lancet. 1983 Feb 26;1(8322):444–446. doi: 10.1016/s0140-6736(83)91440-x. [DOI] [PubMed] [Google Scholar]
  32. Sing C. F., Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet. 1985 Mar;37(2):268–285. [PMC free article] [PubMed] [Google Scholar]
  33. Sing C. F., Moll P. P. Genetics of variability of CHD risk. Int J Epidemiol. 1989;18(3 Suppl 1):S183–S195. [PubMed] [Google Scholar]
  34. Sing C. F., Orr J. D. Analysis of genetic and environmental sources of variation in serum cholesterol in Tecumseh, Michigan. III. Identification of genetic effects using 12 polymorphic genetic blood marker systems. Am J Hum Genet. 1976 Sep;28(5):453–464. [PMC free article] [PubMed] [Google Scholar]
  35. Talmud P. J., Barni N., Kessling A. M., Carlsson P., Darnfors C., Bjursell G., Galton D., Wynn V., Kirk H., Hayden M. R. Apolipoprotein B gene variants are involved in the determination of serum cholesterol levels: a study in normo- and hyperlipidaemic individuals. Atherosclerosis. 1987 Sep;67(1):81–89. doi: 10.1016/0021-9150(87)90267-x. [DOI] [PubMed] [Google Scholar]
  36. Talmud P. J., Lloyd J. K., Muller D. P., Collins D. R., Scott J., Humphries S. Genetic evidence from two families that the apolipoprotein B gene is not involved in abetalipoproteinemia. J Clin Invest. 1988 Nov;82(5):1803–1806. doi: 10.1172/JCI113795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Templeton A. R., Sing C. F., Kessling A., Humphries S. A cladistic analysis of phenotype associations with haplotypes inferred from restriction endonuclease mapping. II. The analysis of natural populations. Genetics. 1988 Dec;120(4):1145–1154. doi: 10.1093/genetics/120.4.1145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Vu Dac N., Mezdour H., Parra H. J., Luc G., Luyeye I., Fruchart J. C. A selective bi-site immunoenzymatic procedure for human Lp[a] lipoprotein quantification using monoclonal antibodies against apo[a] and apoB. J Lipid Res. 1989 Sep;30(9):1437–1443. [PubMed] [Google Scholar]
  39. Wile D. B., Barbir M., Gallagher J., Myant N. B., Ritchie C. D., Thompson G. R., Humphries S. E. Apolipoprotein A-I gene polymorphisms: frequency in patients with coronary artery disease and healthy controls and association with serum apo A-I and HDL-cholesterol concentration. Atherosclerosis. 1989 Jul;78(1):9–18. doi: 10.1016/0021-9150(89)90153-6. [DOI] [PubMed] [Google Scholar]
  40. Xhignesse M., Lussier-Cacan S., Sing C. F., Kessling A. M., Davignon J. Influences of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health. Arterioscler Thromb. 1991 Jul-Aug;11(4):1100–1110. doi: 10.1161/01.atv.11.4.1100. [DOI] [PubMed] [Google Scholar]
  41. Xu C. F., Nanjee M. N., Savill J., Talmud P. J., Angelico F., Del Ben M., Antonini R., Mazzarella B., Miller N., Humphries S. E. Variation at the apolipoprotein (apo) AI-CIII-AIV gene cluster and apo B gene loci is associated with lipoprotein and apolipoprotein levels in Italian children. Am J Hum Genet. 1990 Sep;47(3):429–439. [PMC free article] [PubMed] [Google Scholar]
  42. Zannis V. I., Breslow J. L. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry. 1981 Feb 17;20(4):1033–1041. doi: 10.1021/bi00507a059. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics

RESOURCES